Caribou Biosciences (CRBU) Retained Earnings (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Retained Earnings of $723.6 million for Q1 2026, up 433211.98% year-over-year from N/an in Q1 2025, and up 0.7% quarter-over-quarter from $718.6 million in Q4 2025.
Caribou Biosciences (CRBU) Retained Earnings (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Retained Earnings for 7 consecutive years, with $723.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 433211.98% year-over-year to $723.6 million; the TTM figure through Mar 2026 stood at $723.6 million (up 433211.98% YoY), while the FY2025 annual figure was $718.6 million, up 2.5% from the prior year.
- Retained Earnings climbed to $723.6 million in Q1 2026 per CRBU's latest filing, from $718.6 million in the prior quarter.
- Across five years, Retained Earnings topped out at $723.6 million in Q1 2026 and bottomed at -$570.0 million in Q3 2025.
- Historically, Retained Earnings has averaged -$26.5 million across 5 years, with a median of -$170.2 million in 2022.
- Annual changes were most pronounced in 2024 — Retained Earnings sank 171.99% — and 2026, when it surged 433211.98%.
- Caribou Biosciences' Retained Earnings stood at -$197.2 million in 2022, then sank by 51.76% to -$299.3 million in 2023, then soared by 334.25% to $701.1 million in 2024, then gained by 2.5% to $718.6 million in 2025, then grew by 0.7% to $723.6 million in 2026.
- Business Quant data shows CRBU's Retained Earnings at $723.6 million in Q1 2026, $718.6 million in Q4 2025, and -$570.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | 744.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 744.04 Mn |
| Mar 31, 2026 | 723.63 Mn |
| Dec 31, 2025 | 718.58 Mn |
| Sep 30, 2025 | -570.03 Mn |
| Jun 30, 2025 | 40,000.00 |
| Mar 31, 2025 | 167,000.00 |
| Dec 31, 2024 | 701.08 Mn |
| Sep 30, 2024 | -412.90 Mn |
| Jun 30, 2024 | -378.20 Mn |
| Mar 31, 2024 | -340.50 Mn |
| Dec 31, 2023 | -299.29 Mn |
| Sep 30, 2023 | -264.80 Mn |
| Jun 30, 2023 | 525.37 Mn |
| Mar 31, 2023 | -225.30 Mn |
| Dec 31, 2022 | -197.22 Mn |
| Sep 30, 2022 | -170.20 Mn |
| Jun 30, 2022 | -143.60 Mn |
| Mar 31, 2022 | -116.88 Mn |
| Dec 31, 2021 | -97.79 Mn |
| Sep 30, 2021 | -79.30 Mn |